×
개인정보 취급방침
개인정보 처리방침에 대한 내용을 입력하십시오.
×
이용약관
서비스 이용약관에 대한 내용을 입력하십시오.
Company
비전과 미션
비즈니스 Area
리더십
함께하는 사람들
연혁
Technology
Nexavant®
PeptoVac®
Anti-cancer therapy with PD1 antibody
PulmonoVac®
Tissue and organ regeneration
PeptoC
Pipeline
Pipeline
Product
News & Event
News
Event
Recruit
인재상
복리후생
채용공고
Contact
Contact
Company
비전과 미션
비즈니스 Area
리더십
함께하는 사람들
연혁
Technology
Nexavant®
PeptoVac®
Anti-cancer therapy with PD1 antibody
PulmonoVac®
Tissue and organ regeneration
PeptoC
Pipeline
Pipeline
Product
News & Event
News
Event
Recruit
인재상
복리후생
채용공고
Contact
Contact
ENG
Technology
Technology
Company
Business
Pipeline
News & Event
Recruit
Contact
Nexavant®
Nexavant®
PeptoVac®
Anti-cancer therapy with PD1 antibody
PulmonoVac®
Tissue and organ regeneration
PeptoC
Nexavant®, the novel TLR3 agonist
1
A defined TLR3 agonist with homogeneity
2
RNase A and heat resistant
3
Stable for more than two years at 42℃
4
TLR3 and RIGI agonist without MDA5 activation
5
Scale-up production in GMP grade
6
CAS registered (CAS Number: 2839526-76-8)
7
More than 99% purity in HPLC
8
Capable for more than 10 million dose production/year
9
Strong immune stimulant:
https://pubmed.ncbi.nlm.nih.gov/36761735/
10
Potent anticancer effect:
https://pubmed.ncbi.nlm.nih.gov/38136298/
11
Induce Th1 and CTL response
12
DS for the following development:
Vaccine adjuvant
Anti PD-1 dual therapy
Adjuvant for a cross-reactive flu vaccine
Peptide complex drug development
Nexavant®, a homologous, stable, and high purity product
Homogeneity
Stability I
Purity
Stability II